| Trial ID: | L0374 |
| Source ID: | IRCT20210922052550N1
|
| Associated Drug: |
Metformin
|
| Title: |
Comparison of the effects of Metformin and glorenta (Empagliflozin and linagliptin) on fatty liver of patients with type 2 diabetes in Ilam in 2021
|
| Acronym: |
--
|
| Status: |
Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Condition 1: Fatty liver of type 2 diabetic patients. Condition 2: Fatty liver of type 2 diabetic patients. Condition 3: Fatty liver of type 2 diabetic patients. Condition 4: Fatty liver of type 2 diabetic patients. <br>Fatty (change of) liver, not elsewh
|
| Interventions: |
Intervention 1: Control group: will receive metformin tablets, daily use (once) ?, drug dose: 500 mg, duration of use 12 weeks, number: 84 tablets, how to use: with breakfast, number of use: one daily, manufacturer : Amin Pharmaceutical Company. Intervent
|
| Outcome Measures: |
Determination and comparison of serum levels of alanine aminotransferase at the beginning and end of the study. Timepoint: Measurement of serum levels of alanine aminotransferase at the beginning of the study and one month later. Method of measurement: Serum levels of Alanine aminotransferase will be measured by a reagent laboratory and results will be obtained.Determining and comparing the ratio of abdominal circumference to hip circumference at the beginning and end of the study. Timepoint: Measure the ratio of abdominal circumference to hip circumference at the beginning of the study and one month later. Method of measurement: Measure the ratio of abdominal circumference to hip circumference using an inelastic meter.;Determining and comparing ultrasound findings at the beginning and end of the study. Timepoint: Perform ultrasound at the beginning of the study and three months later. Method of measurement: Perform ultrasound by the selected ultrasound center and get the results.
|
| Sponsor/Collaborators: |
Ilam University of Medical Sciences
|
| Gender: |
All
|
| Age: |
18 yearsno limit
|
| Phases: |
Phase 3
|
| Enrollment: |
100
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients are divided into two groups by simple randomization with a sealed envelope. There are blue and red cards in
|
| Start Date: |
07/11/2021
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
7 February 2022
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/58877
|
